Estrella Names Cynthia Pussinen CEO and Chair; Grants 1M-Share Option
ESLA has more than doubled off its 52-week low of $0.24 on light trading volume (0.1× avg).
Summary
Estrella Immunopharma appointed Cynthia Pussinen as CEO and board chair effective October 25, 2026, with a $250,000 base salary that steps up as the company raises $35M, $55M and $75M, plus a 1,000,000-share option. Cheng Liu moved to President and Chief Scientific Officer.
Key Events · Executive and Board Changes · ESLA
-
New CEO and Chair Appointed
Cynthia Pussinen became Chief Executive Officer, a Class I director and Chairperson of the Board effective October 25, 2026. Cheng Liu ceased as CEO and became Chief Scientific Officer, remaining President and a director.
-
Pay Tied to Funding Milestones
Base salary of $250,000 rises automatically to $400,000, $450,000 and $525,000 when cumulative qualifying funding after October 25, 2026 first exceeds $35.0 million, $55.0 million and $75.0 million, with a 60% target cash bonus.
-
1,000,000-Share Option Grant
Option to purchase 1,000,000 shares under the 2023 Omnibus Incentive Plan, struck at the Nasdaq closing price on the grant date, vesting 25% on October 25, 2027 and the remainder in 36 equal monthly installments.
-
Salaries Still Deferred
The company continues to defer base salaries of Liu and Xu without interest pending completion of additional financing; their amended agreements provide no new equity awards.
Analysis · ESLA · Life Sciences
A new CEO takes over at a company fighting for its listing: a going-concern warning in the August 10-Q, two Nasdaq delisting notices in August and September, and base salaries for the CEO, President and CFO all deferred since May 2026 to conserve cash. Pussinen's pay is built around that reality. Her $250,000 base salary steps up to $400,000, $450,000 and $525,000 only as cumulative qualifying funding passes $35.0M, $55.0M and $75.0M, tying her compensation to the financing the company needs to survive. The main equity incentive is a 1,000,000-share option, priced at the closing price on the grant date, vesting 25% after one year and the rest monthly over three years. Cheng Liu steps down as CEO but stays as President, Chief Scientific Officer and a director, so the science leadership is unchanged. The board also moved to clean up its classified structure, proposing a charter amendment for the 2027 annual meeting that would require the three director classes to be as nearly equal in number as possible.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 30.9% of the 1649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.02%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ESLA was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.7M. The 52-week trading range was $0.24 to $3.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.